Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class III phosphatidylinositol 3-kinase complex (PI3K-III complex)
- Target
- PI3K-III complex
- Molecular classification
- Enzyme complex, Lipid kinase complex, Autophagy regulator
01
Overview
The Class III phosphatidylinositol 3-kinase complex (PI3K-III complex) is a conserved multiprotein assembly responsible for the generation of phosphatidylinositol 3-phosphate (PI3P), a lipid signaling molecule that initiates autophagosome formation and regulates endosomal trafficking. The canonical mammalian complex consists of the catalytic subunit VPS34 (PIK3C3), regulatory subunit VPS15 (PIK3R4), Beclin 1, and either ATG14 or UVRAG, depending on autophagic versus endocytic function. The complex plays a central role in cellular responses to nutrient status, organelle quality control, and maintenance of protein homeostasis. Dysfunction or dysregulation of the PI3K-III complex is implicated in cancer, neurodegeneration, and cardiovascular disease. It is widely studied as a therapeutic target, although broad inhibition may pose safety risks due to its essential roles in autophagy and organ function.
- Other names
- Class III PI3K complexPI3KC3 complexVPS34 complexBeclin 1-PI3K-III complexPIK3C3 complex
02
Mechanism of action
Inhibition of VPS34 kinase activity blocks autophagy, leading to accumulation of cellular waste and altered signaling pathways; Activation or modulation may promote autophagic clearance, neuroprotection, or suppress tumor growth
03
Biological functions
Autophagy initiation (phagophore nucleation and maturation)Vesicular trafficking (endocytosis and lysosomal delivery)Cellular homeostasis (nutrient availability, protein and organelle turnover)Signal transduction mediated by phosphoinositide generation
04
Disease associations
CancerNeurodegenerative disease (e.g., roles in clearance of protein aggregates)Cardiovascular disease (e.g., heart function regulation)Metabolic disease (e.g., diabetes)Inflammation
05
Safety considerations
Potential for toxicity due to impaired autophagy (e.g., liver and heart damage, neurodegeneration)Non-selective inhibition may impair essential homeostatic processes affecting organ function
06
Interacting drugs
Experimental and preclinical small molecules targeting VPS34 kinase activity (no widely approved drugs yet; several molecule inhibitors under investigation for cancer and neurodegeneration)
07
Biomarkers
Accumulation of LC3-II protein (marker of autophagic flux)Increased p62/SQSTM1 (defective autophagy marker)Polyubiquitinated proteins in tissue samples
Beyond the preview
Go deeper on Class III phosphatidylinositol 3-kinase complex (PI3K-III complex).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Class III phosphatidylinositol 3-kinase complex (PI3K-III complex).